News2 mins ago
HARMONY BIOSCIENCES COMPLETES ENROLLMENT OF PHASE 3 REGISTRATIONAL INTUNE STUDY IN IDIOPATHIC HYPERSOMNIA
PLYMOUTH MEETING, Pa., May 25, 2023 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for...
